eribulin
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Mar 1, 2009 → May 1, 2011
NCT ID
NCT00908908About eribulin
eribulin is a phase 1 stage product being developed by Eisai for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00908908. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03840772 | Phase 2 | Completed |
| NCT03637868 | Phase 2 | Withdrawn |
| NCT03331250 | Phase 2 | Active |
| NCT03027245 | Pre-clinical | Completed |
| NCT01669252 | Phase 2 | Completed |
| NCT00908908 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Tumors